GRIMALDI, FRANCESCO
 Distribuzione geografica
Continente #
AS - Asia 1.986
NA - Nord America 1.498
EU - Europa 1.319
SA - Sud America 217
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 5.088
Nazione #
US - Stati Uniti d'America 1.424
SG - Singapore 818
RU - Federazione Russa 581
CN - Cina 414
VN - Vietnam 377
IT - Italia 272
BR - Brasile 187
HK - Hong Kong 126
DE - Germania 93
FR - Francia 74
GB - Regno Unito 58
NL - Olanda 53
FI - Finlandia 49
IN - India 49
JP - Giappone 44
CA - Canada 42
BD - Bangladesh 41
IE - Irlanda 30
KR - Corea 30
CI - Costa d'Avorio 24
SE - Svezia 22
UA - Ucraina 22
MX - Messico 19
ZA - Sudafrica 17
AT - Austria 14
PL - Polonia 14
AR - Argentina 13
IQ - Iraq 13
LT - Lituania 10
PH - Filippine 10
ES - Italia 9
PK - Pakistan 9
TH - Thailandia 9
ID - Indonesia 7
TR - Turchia 7
EC - Ecuador 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
CZ - Repubblica Ceca 5
JM - Giamaica 5
KE - Kenya 5
BE - Belgio 4
TW - Taiwan 4
UZ - Uzbekistan 4
CH - Svizzera 3
IL - Israele 3
MA - Marocco 3
NP - Nepal 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
DZ - Algeria 2
EU - Europa 2
HN - Honduras 2
JO - Giordania 2
KW - Kuwait 2
KZ - Kazakistan 2
MY - Malesia 2
PY - Paraguay 2
BS - Bahamas 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
EG - Egitto 1
GA - Gabon 1
HR - Croazia 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MG - Madagascar 1
ML - Mali 1
MR - Mauritania 1
MU - Mauritius 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
RE - Reunion 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
YE - Yemen 1
Totale 5.088
Città #
Singapore 409
San Jose 221
Moscow 155
Ashburn 146
Hefei 134
Chandler 124
Hong Kong 119
Ho Chi Minh City 104
Beijing 90
Naples 80
Hanoi 75
Santa Clara 60
Los Angeles 53
Lauterbourg 41
The Dalles 41
Council Bluffs 38
Tokyo 37
Amsterdam 36
Millbury 34
New York 33
Munich 30
Dong Ket 28
Seoul 23
Napoli 22
Des Moines 19
Da Nang 18
Princeton 18
Redondo Beach 18
Frankfurt am Main 17
Nanjing 16
Boston 15
Buffalo 15
Milan 15
São Paulo 15
Dallas 13
Helsinki 13
Stockholm 13
Turku 13
Denver 12
Haiphong 12
London 12
Kochi 11
Montreal 11
Ottawa 11
Lawrence 10
Seattle 10
Toronto 10
Warsaw 10
Rome 9
Brooklyn 8
Chennai 8
Houston 8
Orem 8
Poplar 8
Redwood City 8
Chicago 7
Falkenstein 7
Johannesburg 7
Lappeenranta 7
Nanchang 7
Nuremberg 7
Phoenix 7
Porto Alegre 7
Wilmington 7
Atlanta 6
Bình Phước 6
Dublin 6
Mexico City 6
New Delhi 6
Rio de Janeiro 6
San Francisco 6
Baghdad 5
Campagna 5
Changsha 5
Dhaka 5
Florence 5
Querétaro 5
Quito 5
Shenyang 5
Tianjin 5
Vienna 5
Brasília 4
Brussels 4
Bến Tre 4
Cape Town 4
Hamilton 4
Istanbul 4
Manchester 4
Nairobi 4
Norwalk 4
Salvador 4
Tashkent 4
Ankara 3
Aracaju 3
Bangkok 3
Bengaluru 3
Birmingham 3
Biên Hòa 3
Bắc Ninh 3
Can Tho 3
Totale 2.740
Nome #
A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison 184
(1-3)-β-d-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations 175
Intravascular Complications of Central Venous Catheterization by Insertion Site in Acute Leukemia during Remission Induction Chemotherapy Phase: Lower Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Study 171
Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better?. 148
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study 145
JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. 143
XM02 PLUS CHEMOTHERAPY IS SAFE AND EFFECTIVE IN STEM CELL MOBILIZATION FOR PATIENTS CANDIDATED TO AUTOLOGOUS STEM CELL TRANSPLANTATION 139
LONG-TERM FOLLOW UP OF ALENTUZUMAB-BASED IMMUNOSUPPRESSION FOR THE TREATMENT OF IMMUNE-MEDIATED BONE MARROW FAILURE SYNDROMES 137
Acute immune toxicity during anti-thymocyte globulin: That's CARPA! 136
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis 136
Twenty years of the Italian Fanconi Anemia Registry: Where we stand and what remains to be learned 133
Myeloid Sarcoma of the Breast as Blast Phase of JAK2-Mutated (Val617Phe Exon 14p) Essential Thrombocythemia: A Case Report and a Systematic Literature Review 131
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 131
THIOTEPA AND MELPHALAN AS NEW CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE LYELOMA 131
PEGYLATED-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE 130
PEG-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : A SINGLE-CENTRE EXPERIENCE 130
Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. 129
Retroperitoneal extramedullary relapse after blinatumomab in acute lymphoblastic leukemia failing haplo-identical bone marrow transplantation. 125
1139 poster ASYMPTOMATIC HEART DISEASE AFTER MEDIASTINAL IRRADIATION IN HODGKIN'S LYMPHOMA: PRELIMINARY FINDINGS 123
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients 122
Thyroid V30 Predicts Radiation-Induced Hypothyroidism in Patients Treated With Sequential Chemo-Radiotherapy for Hodgkin’s Lymphoma 121
Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better? 114
Long-term Cryopreserved Autologous Hematopoietic Stem Cells Following Azacytidine to Successfully Treat Severe Invasive Pulmonary Aspergillosis After Therapy-Related Myelodysplastic Syndrome and CD8+ T-cell Autoimmune Disorders: A Case Report 112
Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy. 112
Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. 111
Deregulation of New Cell Death Mechanisms in Leukemia 110
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 108
Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary review 106
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 106
Epidemiology of Acquired Bone Marrow Failure 105
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report 103
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients 101
Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center 98
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study 95
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years 84
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph- B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 80
Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy 79
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program 75
Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS 67
Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia 65
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI) 64
Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study 62
Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells 59
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study 55
Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts 53
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 51
Gallbladder Myeloid Sarcoma Associated With NPM1 Mutated Acute Myeloid Leukemia 49
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 31
Totale 5.175
Categoria #
all - tutte 14.837
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.837


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 0 3 30
2021/2022213 3 4 2 2 3 7 3 4 26 20 69 70
2022/2023295 28 14 10 9 52 42 2 38 52 31 13 4
2023/2024155 5 33 13 7 8 19 5 32 0 0 24 9
2024/20251.347 35 36 25 22 39 91 153 111 73 152 493 117
2025/20262.858 311 243 337 320 538 81 252 172 298 211 95 0
Totale 5.175